Why the study?
Does prediabetes worsen clinical outcomes, angiographic results, and incidence of MACE in patients presenting with STEMI compared to non-diabetics?
Cohort (n=70)
No
Does prediabetes worsen clinical outcomes, angiographic results, and incidence of MACE in patients presenting with STEMI compared to non-diabetics?
In patients presenting with STEMI, prediabetes is associated with more complex coronary anatomy, worse LV dysfunction, and significantly higher rates of in-hospital MACE and mortality compared to non-diabetics.
Answers are grounded in this paper and cite their sources.
Prediabetes was associated with higher MACE after STEMI; hypothesis-generating and should not yet change practice.
Background: Pre diabetes is a definite risk factor in cases of STEMI. This study was aimed to compare various clinical outcomes, coronary angiographic results and incidence of major adverse cardiovascular event (MACE) in prediabetic patients presented with STEMI with those of non prediabetic STEMI patients in a tertiary care centre. Methods: Study was conducted in prediabetic patients presented with STEMI whose fasting serum glucose and glycated hemoglobin level were 100-125 mg/dl and 5.7-6.4%, were respectively. Age and sex matched non prediabetic patients with STEMI was selected as control group. Demographic variables were taken. Further the clinical presentations; findings of coronary angiogram; electrocardiogram (ECG) and 2D echo; morbidity and cardiac mortality were collected and subjected to statistical analysis. Results: Total of 70 patients (35 prediabetic and 35 non prediabetic control) with ACS STEMI were included in the prospective study. The prediabetic patients with ACS STEMI were found with clinical presentation (Killip class III and IV); ECG manifestations (Tachyarrythmia); 2 D echo (Moderate and severe left ventricular dysfunction); angiographic findings (Double and Triple vessel disease, Right coronary artery(RCA), Left circumflex artery (LCX), Long Stents); morbidity (MACE and site hematoma) and cardiac mortality more than the non prediabetic control group.
No takes yet. Share an insight, caveat, or question.
S. Thrudeep (2016) conducted a cohort in ST-Elevation Myocardial Infarction (STEMI) (n=70). Prediabetes vs. Normoglycemia (Non-diabetic) was evaluated on Major adverse cardiovascular events (MACE) (p=0.03).
Synapse has enriched 10 related papers. Consider them for comparative context: